Experimental KRRO-110 trial for rare lung condition halted early
NCT ID NCT06677307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called KRRO-110 in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause lung and liver damage. The goal was to check safety and how the drug moves through the body. However, the trial was terminated before completion, so no final conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KRRO-110 (an experimental drug given intravenously)
What this could lead to
If successful, KRRO-110 could help control Alpha-1 Antitrypsin Deficiency by raising protective enzyme levels, potentially slowing lung damage.
What could go wrong
This early-stage trial was terminated, so results are unknown. The drug is first-in-human, meaning safety and effectiveness are not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AATD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
St. Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia